FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Breakthrough Status for Heart Failure Device

[ Price : $8.95]

FDA grants Alleviant Medical a breakthrough designation for its no-implant atrial shunt technology for treating heart failure with...

Create Labeling-only NDA: Report

[ Price : $8.95]

Three RebootRx executives call on FDA to create a labeling-only 505(b)(2) NDA pathway to allow non-manufacturers to seek approval ...

Draft Guide on Optical Imaging Drugs

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance entitled Developing Drugs for Optical Imaging.

Guide on Developing Obesity Drugs

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance entitled Obesity and Overweight: Developing Drugs and Biological Pro...

6 Human Cell, Tissue Donor Eligibility Guides

[ Price : $8.95]

FDA publishes one draft general and five specific immediately effective guidances to help establishments understand regulations go...

Priority Review for Verastem Ovarian Cancer NDA

[ Price : $8.95]

FDA grants a priority review for a Verastem Oncology NDA for avutometinib, an oral RAF/MEK clamp for use in combination with defac...

Diversity Action Plan Submissions Up

[ Price : $8.95]

FDA says voluntary submission of clinical study diversity action plans increased from FY 2023 to FY 2024.

XO Biologix Marketing Unapproved, Adulterated Drug

[ Price : $8.95]

FDA warns Austin, TX-based XO Biologix that it is marketing an unapproved adulterated and misbranded product derived from amniotic...

FDA Fast Track for J&J Alzheimers Drug

[ Price : $8.95]

FDA grants fast-track designation to posdinemab, an investigational J&J Alzheimers drug.

1st Cycle NDA Approvals Fall in 2024: CDER

[ Price : $8.95]

A CDER drug approval reports shows that first-cycle NDA approvals fell in 2024 to 74% (37 of the 50 novel drugs approved) from 84%...